Robert Gallotto serves as President and Chief Executive Officer of Anagram Therapeutics. Mr. Gallotto is an experienced pharmaceutical executive, with a 35-year track record of building companies focused in cystic fibrosis and other rare diseases. Prior to joining Anagram, Mr. Gallotto was the co-founder and served as President of Alcresta Therapeutics, a company focused on developing products for cystic fibrosis and other rare diseases. Mr. Gallotto built the company from an idea to the successful launch of its first product, RELiZORB, a novel medical device awarded the 2016 Medical Device Design Excellence Gold Medal Award. Mr. Gallotto has been involved with several collaborations with the CF Foundation over the past 20 years and is the inventor of numerous issued patents. Mr. Gallotto also served as co-founder and Chief Operating Officer of Allena Pharmaceuticals. Prior to Alcresta and Allena, Mr. Gallotto served as Chief Business Officer of Alnara Pharmaceuticals, until the company was acquired by Eli Lilly. Mr. Gallotto also served as Vice President of strategic planning, business, and commercial development for Altus Pharmaceuticals. Before joining Altus, Mr. Gallotto served in various positions in sales and marketing, business development and product management with companies such as Biogen, Ares-Serono, Sage BioPharma and The Upjohn Company. Mr. Gallotto holds a B.S. in biology from Stonehill College.

David Brown serves as Anagram Therapeutics' Chief of Technology Development with more than twenty-five years of experience in pharmaceutical and medical device innovation and commercial manufacturing. Mr. Brown provides leadership of product and process development, program management, and supply chain. Prior to joining Anagram, Mr. Brown was Vice President of Technical Operations at Alcresta Therapeutics, Vice President of Technical Operations at Stealth Biotherapeutics, and Strategic Account Executive for Patheon. Mr. Brown earned a B.S. in chemical engineering from Northeastern University.

Don G. Burstyn, Ph.D. serves as a Senior Advisor in both regulatory affairs and quality. Dr. Burstyn received his Doctorate from the Department of Microbiology, University of Maryland, College Park. Dr. Burstyn spent 9 years working at the United States Food and Drug Administration (FDA), Division of Bacterial Products, primarily on the regulation and development of vaccines. During his tenure at the Agency he received the FDA Award of Merit and was part of an FDA Group Recognition Award. Subsequently, Dr. Burstyn spent almost 25 years in leadership positions at various biopharmaceutical companies, including Biogen, Alkermes, Altus, and Alnara. For the past 12 years Dr. Burstyn has served as an independent consultant to the industry. During his career at private and public companies, and as a consultant, Dr. Burstyn participated in the development of over 30 clinical products, including proteins, peptides, and small molecules. Dr. Burstyn has been involved with five product approvals.

Marci Clarkin, RN, BS is the Vice President of Clinical Strategic Operations and is responsible for providing strategic and operational leadership at Anagram. Previously, Ms. Clarkin served as the Senior Vice President Global Clinical Operations at uniQure where she directed and supported team delivery/strategy for on time recruitment and key data milestone delivery for the Hemophilia B gene therapy program. Her background includes leadership roles in Quality and Compliance where she developed and implemented global systems and processes while assuring compliance and strategic risk mitigation across both development and commercial products for organizations such as Visterra Inc., Radius Health Inc., Boston Scientific Corporation and AMAG Pharmaceuticals, Inc. Marci earned her Bachelor of Science, Nursing from Cedar Crest College Allentown, PA.

Pamela Nelson serves as Executive Vice President Regulatory Affairs. Ms. Nelson brings over 28 years of experience in the biopharmaceutical industry, leading global regulatory strategies for all phases of development through commercialization across a range of therapeutic areas. Before joining Anagram Therapeutics, she served as Senior Vice President, Regulatory Affairs at Lyra Therapeutics. Previously, Ms. Nelson held regulatory positions at Avedro, Alnara Pharmaceuticals, Altus Pharmaceuticals, Alkermes and Genzyme. Ms. Nelson holds a B.A. in English and an M.Ed in education administration from the University of Massachusetts at Amherst.

Sophia Sassoon serves as the Vice President of Quality for Anagram Therapeutics. She is responsible for providing strategic and operations leadership through the entire product lifecycle with a strong emphasis on GxP compliance. Prior to joining Anagram, Ms. Sassoon served as the Sr. Director of Quality at 89bio where she was responsible for providing Quality oversight for all nonclinical and clinical programs as well as providing oversight of all GxP vendors. Her background includes leadership roles in Quality and Compliance where she developed and implemented global systems and processes while assuring compliance and strategic risk mitigation across both development and commercial products for organizations such as 89bio, RedHill Biopharma, Humacyte, and Grifols. Ms. Sassoon earned her Bachelor of Pharmacy from the University of Poona, India and has her M.S. in pharmacy administration from the University of the Sciences, Philadelphia.

Hugh Wight serves as Chief, Corporate Development with Anagram Therapeutics. Mr. Wight is well-positioned to translate corporate vision into executable strategies to deliver marketable products and transform lives. Prior to joining Anagram, Mr. Wight held multiple positions of increasing responsibility at Allena Pharmaceuticals Inc., including his most recent role as Senior Vice President, Technical Operations. He has also had successful engagements with Alnara Pharmaceuticals, Altus Pharmaceuticals and Alkermes. Mr. Wight has over 30 years of program and portfolio management experience developing biologics and small molecules from the pre-investigational new drug application stage to marketing authorization. Mr. Wight received a B.S. in microbiology from the University of Maine.